Double Materiality Assessment
for Healthcare

Double materiality assessment for Healthcare

Healthcare entities (hospitals, pharmaceutical manufacturers, medical device companies, and care providers) present a materiality profile shaped by the sector's direct interaction with human health, its use of hazardous substances, and its workforce intensity. A mid-sized hospital group with 3,000 employees, pharmaceutical waste streams, energy-intensive sterilisation processes, and clinical research activities will find at least five ESRS topics material. The assessment under ESRS 1.20-33 must reflect the full operational and value chain scope, including upstream supply chains for pharmaceuticals, medical devices, and single-use plastics.

E1 Climate change is material for most healthcare entities. Hospitals are energy-intensive (operating theatres, HVAC, imaging equipment), and the UK NHS estimated in 2020 that the health sector accounts for 4-5% of national carbon emissions in major economies. Pharmaceutical manufacturing adds process emissions and significant Scope 3 from active pharmaceutical ingredient (API) supply chains, often concentrated in India and China. E2 Pollution is a defining topic for healthcare. Pharmaceutical residues in wastewater, anaesthetic gas emissions (desflurane has a global warming potential 2,540 times that of CO2), clinical waste incineration, and hazardous chemical storage all trigger impact materiality. The EU's revised Urban Wastewater Treatment Directive (2024) adds financial materiality by requiring extended producer responsibility for pharmaceutical pollution. S1 Own workforce is material given the sector's reliance on clinical staff working long shifts in physically and psychologically demanding conditions. Nursing shortages across Europe add financial materiality through agency staff costs and service delivery risk. S3 Affected communities applies where healthcare entities operate in areas with limited healthcare access, or where pharmaceutical pricing decisions affect community health outcomes. S4 Consumers and end-users covers patient safety, informed consent, clinical trial ethics, and equitable access to treatment. G1 Business conduct addresses procurement integrity (medical device kickbacks remain an enforcement priority), research ethics, and interactions with healthcare professionals.

Assurance providers reviewing healthcare assessments flag the omission of E2 as the most common gap. Entities focus on E1 because climate reporting is more established, but E2 Pollution often has higher severity scores in healthcare given the direct human health consequences of pharmaceutical contamination and clinical waste mismanagement. A second finding is the failure to assess S3 for pharmaceutical companies whose pricing or distribution decisions affect community health outcomes in lower-income countries. ESRS S3 explicitly covers access to products and services as an impact pathway.

Healthcare entities should structure the assessment by operational segment: clinical operations (hospitals, clinics), pharmaceutical manufacturing, research and development, and support services. Each segment generates different sustainability matters. Clinical operations drive E1 (energy), E2 (waste, anaesthetic gases), and S1 (workforce). Pharmaceutical manufacturing adds E2 (API waste, solvent emissions) and E5 (packaging, single-use plastics). R&D drives S4 (clinical trial ethics) and G1 (research integrity). Score each matter using facility-level data where available: energy bills, waste transfer notes, workforce absence rates, patient safety incident reports, and regulatory inspection outcomes.